Which statement best describes Beclin-1's clinical utility according to multivariable analysis?

• A. Beclin-1 immunolabeling is the best independent predictive biomarker for identifying which dogs are likely to fail adjunctive therapy, regardless of the tumor's histological grade or mitotic count
• B. Beclin-1 immunolabeling has limited predictive value
• C. Beclin-1 immunolabeling only predicts outcomes for high-grade tumors
• D. Beclin-1 immunolabeling remains unhelpful when considering tumor grade or mitotic count

Answer: (A)

Multivariable analysis tests whether a biomarker adds predictive information above and beyond other known factors, such as histologic grade and mitotic count. Beclin-1 immunolabeling remains significantly associated with failure of adjunctive therapy even after adjusting for those traditional tumor characteristics, making it the strongest independent predictor among the variables considered. This means Beclin-1 provides prognostic insight that is not explained by how aggressive the tumor looks under histology or how many cells are dividing, which is why it’s described as the best independent predictive biomarker.

Biologically, Beclin-1 is involved in autophagy, a process that can help cancer cells survive stress from therapy. If Beclin-1 expression captures a tumor’s capacity to resist adjunctive treatment, its immunolabeling would predict treatment failure across a range of tumor grades and mitotic counts, aligning with the finding of independence from those factors. The other statements imply limited or conditional usefulness tied to grade or mitotic activity, which contradict the multivariate result showing Beclin-1’s robust, grade- and mitotic-count–independent predictive value.